Delivers fastest and easiest workflow with the lowest sample input
for targeted resequencing studies
SAN DIEGO--(BUSINESS WIRE)--Jul. 17, 2012--
Illumina, Inc. (NASDAQ: ILMN) today introduced Nextera Exome and Custom
Enrichment kits, the Company’s latest targeted resequencing solutions
offering sample preparation and enrichment in a single, integrated
workflow. Leveraging the speed of Nextera technology and supporting the
industry’s lowest DNA sample input requirements (50 ng), the new kits
enable researchers to quickly and economically perform a wide range of
studies – from small, focused gene panels to full human exomes.
Upfront sample preparation is an often difficult and time-consuming task
for targeted resequencing studies. Nextera Exome and Custom Enrichment
kits replace the lengthy sample preparation protocols with a single,
streamlined workflow that can be performed in less than three hours and
removes the requirement for mechanical DNA fragmentation. The kits
integrate the ease of Nextera sample preparation with the company’s
established TruSeq® Exome and Custom Enrichment solutions for a
fast, scalable and highly efficient approach to targeted resequencing.
Offering excellent data quality with a low DNA sample input requirement,
the kits enable researchers to study small samples, while retaining
sufficient material for future analysis.
“Nextera Enrichment kits deliver superior performance on all fronts with
a simple, rapid workflow that eliminates almost an entire day of
preparation time,” said Christian Henry, Senior Vice President and
General Manager, Genomic Solutions. “Developed, tested, and optimized
for Illumina sequencing platforms, Nextera Enrichment kits make targeted
resequencing more broadly available to researchers who are interested in
performing studies on DNA samples that may only be available in limited
"The combination of Nextera library prep and TruSeq capture produces a
simple workflow and high quality data. It will allow us to process large
numbers of samples without investing in automation systems and opens up
capture-based sequencing to samples that would not have been accessible
due to DNA input constraints,” said Dr. James Hadfield, Head of
Genomics, Cancer Research, UK. “We have been able to perform custom and
exome capture as well as low coverage genome sequencing from the same 50
ng input DNA."
Nextera Exome Enrichment kits offer:
Comprehensive coverage of the human exome, with greater than 62 Mb of
both coding regions and untranslated regions (UTRs).
Excellent data quality with high enrichment rates and premier coverage
The ability to fully customize content with Illumina’s DesignStudio, a
free online tool for Illumina customers.
Industry-best DNA input of 50 ng.
A unique 12-plex pre-enrichment sample pooling, reducing hands-on time
and enabling the most cost-effective and operationally efficient
Nextera Enrichment Sample Preparation Kits are now shipping. For more
information, visit www.illumina.com/NexteraEnrich.
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
Source: Illumina, Inc.
Kevin Williams, MD